CSG Shares Under Pressure as Explosia Acquisition Looms Over Strong Q1 Print

Czechoslovak Group sees revenue up 13.8% and profit surge 83%, but shares slide 57% from highs amid uncertainty over a potential €600-680M Explosia acquisition.

The Czechoslovak Group (CSG) finds itself in an odd spot: operating metrics are firing on all cylinders, yet the stock keeps sliding. First-quarter revenue climbed 13.8% to €1.54 billion and net profit surged 83% to €299 million, but the share price has tumbled roughly 57% from its 52-week high of €36.05 to the current €15.50. After closing at €16.07 on Tuesday, it shed nearly 13% in the past seven days alone.

Much of the market’s unease stems from a potential blockbuster acquisition that remains anything but certain. Czech media have flagged Explosia, a state-owned manufacturer of explosives, propellants and ammunition, as a possible target for CSG. The defence group has long touted vertical integration as a key margin driver — it explicitly cited this pillar alongside capacity expansion in its Q1 2026 report. Yet the government has not published any terms for a sale, and CSG has not confirmed a binding offer.

The price tag floated in local press ranges from 15 billion to 17 billion Czech koruna (roughly €600 million to €680 million). That sum would be manageable but nontrivial for CSG, which ended the first quarter with net debt of €2.23 billion and a net-debt-to-EBITDA ratio of 1.3. Valuing Explosia is complicated: its 2025 figures have not been released, and the last available figure — an EBITDA of 621 million koruna for 2024 — may or may not reflect the current defence cycle. Any bid would force investors to scrutinise acquisition discipline and financing terms.

CSG is not alone in the hunt. Czech media also name STV and Colt as potential suitors. Moreover, Colt CZ Defence Solutions signed a cooperation memorandum with Explosia in March 2026 covering ammunition certification, modifications for the Czech army and NATO countries, and R&D. Prague will likely weigh price against national-security conditions, antitrust concerns and whether a bidder with existing collaborative ties gets preference.

Analysts, for their part, remain largely bullish. The consensus on the stock is a “Strong Buy” based on ten ratings, with a median price target of €32.05 — implying roughly 100% upside from current levels. Berenberg did trim its estimates and target after mixed performance across CSG’s business units in the opening quarter, but the broader sentiment is still optimistic.

The defence segment continues to carry the weight. The Defence Systems division posted 26% revenue growth to €1.25 billion, and the group’s total order backlog reached around €17 billion — up 15% since year-end. CSG is guiding for full-year 2026 revenue of €7.4–€7.6 billion with an EBIT margin of 24–25%, while large-calibre ammunition output is expected to rise from 550,000 units last year to about 850,000 by year-end.

Yet the market demands more than a full order book. Technically, the stock sits about 21% below its 50-day moving average and just 2.19% above its recent trough. The annualised 30-day volatility has hit 80.38%, underscoring how jittery trading has become. Every industry headline — whether on M&A or trade shows — now amplifies moves.

One such event is the HEMUS 2026 defence expo, which kicked off Wednesday in Plovdiv, Bulgaria. Opened by President Iliana Iotova, the fair brings together 216 companies from 28 countries, with 18 Czech exhibitors among them. Covering more than 5,000 square metres, the show features robotics, artificial intelligence, drone technology — fields that are gaining traction across European defence. High-level forums are scheduled for Thursday, followed by live-fire demonstrations on Friday, with more than 16 international delegations attending.

For CSG, the near-term narrative hinges on whether it can convert operational momentum into a sustained stock recovery. The Explosia speculation adds an extra layer of tension: if a bid materialises, it will test management’s acquisition discipline; if it fizzles, the market might shift its focus back to the underlying business — and the record €17 billion order book. Until Prague clarifies the sale process or CSG confirms an offer, Explosia remains a strategic watchpoint rather than a confirmed catalyst.